<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00572325</url>
  </required_header>
  <id_info>
    <org_study_id>BRONC CONCURR MLD</org_study_id>
    <nct_id>NCT00572325</nct_id>
  </id_info>
  <brief_title>Concurrent Chemo-radiation Form NSCLC to a Individualized MLD</brief_title>
  <acronym>BRONC CONC MLD</acronym>
  <official_title>Concurrent Chemo-radiotherapy for Stage III Non-small Cell Lung Cancer ta an Individualized MLD</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Maastricht Radiation Oncology</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Maastricht Radiation Oncology</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Our group has shown in a modeling study that increasing the radiation dose to pre-specified&#xD;
      normal tissue dose constrains could lead to increased TCP with the same NTCP in patients with&#xD;
      non-concurrent chemo-radiation. In a subsequent phase I trial, in patients receiving&#xD;
      non-concurrent chemo-radiation we showed the safety of this approach. Here,we want to&#xD;
      investigate its efficacy in a prospective study in patients with stage III NSCLC, who are&#xD;
      selected for radical concurrent radiotherapy&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Eligible patients (see below) will receive radiotherapy to the primary tumor and the&#xD;
      initially involved mediastinal lymph nodes to the following MLD (Mean Lung Dose):&#xD;
&#xD;
        -  MLD=19 Gy when Fev1 and DLCO&gt;50% of the predicted value&#xD;
&#xD;
        -  MLD=15 Gy when Fev1 and/or DLCO 40-49% of the predicted value&#xD;
&#xD;
        -  MLD=10 Gy when Fev1 and/or DLCO &lt;40% of the predicted value&#xD;
&#xD;
      Other dose-constrains: spinal cord max: 54 Gy, brachial plexus (Dmax):66 Gy Minimum tumor&#xD;
      dose:54 Gy. Maximal tumor dose:69 Gy&#xD;
&#xD;
      Radiotherapy will be delivered as follows:&#xD;
&#xD;
        1. First 3 weeks: 30 fractions: twice-daily fractions of 1.5 Gy, with 8 to 10 h as&#xD;
           interfraction-interval, 5 days per week Total dose;45Gy/30 fractions&#xD;
&#xD;
        2. Thereafter: once-daily fractions of 2.0 Gy, 5 days per week until the target dose has&#xD;
           been reached.&#xD;
&#xD;
      The radiation doses will be specified according to ICRU 50. Lung density corrections will be&#xD;
      applied, as well as all standard QA procedures. Technical requirements are the same as in&#xD;
      standard practice at MAASTRO clinic.&#xD;
&#xD;
      Chemotherapy schedules allowed:&#xD;
&#xD;
        1. 1-2 cycles induction chemotherapy; any type will be registered.&#xD;
&#xD;
        2. concurrent part:(day1= first day of radiotherapy)&#xD;
&#xD;
             1. cisplatin - vinorelbine&#xD;
&#xD;
                  -  Cisplatin 50 mg/m2 day 2 and day 9&#xD;
&#xD;
                  -  Vinorelbine 20 mg/m2 day 2 and day 9&#xD;
&#xD;
                  -  Cisplatin 40mg/m2 day 23&#xD;
&#xD;
                  -  Vinorelbine 15mg/m2 day 23 and day 30&#xD;
&#xD;
             2. cisplatin - docetaxel&#xD;
&#xD;
                  -  Cisplatin 50 mg/m2 day 2,9 and 29&#xD;
&#xD;
                  -  Docetaxel 20 mg/m2 day 2, 9, 16, 23 and 29&#xD;
&#xD;
             3. cisplatin - etoposide&#xD;
&#xD;
                  -  Cisplatin 60 mg/m2 day 1&#xD;
&#xD;
                  -  Docetaxel 120 mg/m2 day 1-3&#xD;
&#xD;
      Q 3 weeks, 3 cycles&#xD;
&#xD;
      When the calculated creatinin clearance is less than 60 ml/min, cisplatin may be substituted&#xD;
      for carboplatin&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>August 2006</start_date>
  <completion_date type="Actual">May 2009</completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>death</measure>
    <time_frame>2,3 and 5 years</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>-progression-free interval -Dyspnea (CTCAE 3.0) -Dysphagia (CTCAE 3.0) -Patterns of recurrence</measure>
    <time_frame>2,3 and 5 years</time_frame>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Actual">180</enrollment>
  <condition>Non-small Cell Lung Cancer</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <description>Inclusion criteria&#xD;
Histological or cytological proven NSCLC&#xD;
UICC stage I-III&#xD;
Performance status 0-2&#xD;
FeV1 and DLCO at least 30% of age-predicted value&#xD;
Exclusion criteria:&#xD;
Not NSCLC or mixed NSCLC and other histologies (e.g. small cell carcinoma)&#xD;
stage IV&#xD;
performance status 3 or more&#xD;
FeV 1 or DLCO&lt; 30% of the age-predicted value</description>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        -  Histological or cytological proven NSCLC&#xD;
&#xD;
          -  UICC stage I-III&#xD;
&#xD;
          -  Performance status 0-2&#xD;
&#xD;
          -  FeV 1 and DLCO at least 30% of the age-predicted value&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Histological or cytological proven NSCLC&#xD;
&#xD;
          -  UICC stage I-III&#xD;
&#xD;
          -  Performance status 0-2&#xD;
&#xD;
          -  FeV 1 and DLCO at least 30% of the age-predicted value&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Not NSCLC or mixed NSCLC and other histologies (e.g. small cell carcinoma)&#xD;
&#xD;
          -  UICC stage IV&#xD;
&#xD;
          -  Performance status 3 or more&#xD;
&#xD;
          -  FeV 1 and DLCO &lt; 30% of the age-predicted value&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Dirk De Ruysscher, MD,PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>MAASTRO clinic, Maastricht Radiation Oncology</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>MAASTRO clinic, Maastricht Radiation Oncology</name>
      <address>
        <city>Maastricht</city>
        <zip>6202 AZ</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Netherlands</country>
  </location_countries>
  <verification_date>July 2010</verification_date>
  <study_first_submitted>December 12, 2007</study_first_submitted>
  <study_first_submitted_qc>December 12, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 13, 2007</study_first_posted>
  <last_update_submitted>July 20, 2010</last_update_submitted>
  <last_update_submitted_qc>July 20, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 21, 2010</last_update_posted>
  <responsible_party>
    <name_title>MAASTRO clinic</name_title>
    <organization>MAASTRO clinic</organization>
  </responsible_party>
  <keyword>radiotherapy</keyword>
  <keyword>NSCLC</keyword>
  <keyword>stage III non-small cell lung cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

